414 related articles for article (PubMed ID: 33333772)
1. Palmitoylethanolamide: A Nutritional Approach to Keep Neuroinflammation within Physiological Boundaries-A Systematic Review.
Petrosino S; Schiano Moriello A
Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33333772
[TBL] [Abstract][Full Text] [Related]
2. Mast cell-glia axis in neuroinflammation and therapeutic potential of the anandamide congener palmitoylethanolamide.
Skaper SD; Facci L
Philos Trans R Soc Lond B Biol Sci; 2012 Dec; 367(1607):3312-25. PubMed ID: 23108549
[TBL] [Abstract][Full Text] [Related]
3. Amyotrophic lateral sclerosis treatment with ultramicronized palmitoylethanolamide: a case report.
Clemente S
CNS Neurol Disord Drug Targets; 2012 Nov; 11(7):933-6. PubMed ID: 22998138
[TBL] [Abstract][Full Text] [Related]
4. Increased levels of palmitoylethanolamide and other bioactive lipid mediators and enhanced local mast cell proliferation in canine atopic dermatitis.
Abramo F; Campora L; Albanese F; della Valle MF; Cristino L; Petrosino S; Di Marzo V; Miragliotta V
BMC Vet Res; 2014 Jan; 10():21. PubMed ID: 24423192
[TBL] [Abstract][Full Text] [Related]
5. N-Palmitoylethanolamine and Neuroinflammation: a Novel Therapeutic Strategy of Resolution.
Skaper SD; Facci L; Barbierato M; Zusso M; Bruschetta G; Impellizzeri D; Cuzzocrea S; Giusti P
Mol Neurobiol; 2015 Oct; 52(2):1034-42. PubMed ID: 26055231
[TBL] [Abstract][Full Text] [Related]
6. Synaptic Effects of Palmitoylethanolamide in Neurodegenerative Disorders.
Assogna M; Di Lorenzo F; Martorana A; Koch G
Biomolecules; 2022 Aug; 12(8):. PubMed ID: 36009055
[TBL] [Abstract][Full Text] [Related]
7. Palmitoylethanolamide: A Natural Compound for Health Management.
Clayton P; Hill M; Bogoda N; Subah S; Venkatesh R
Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34069940
[TBL] [Abstract][Full Text] [Related]
8. Impaired Duodenal Palmitoylethanolamide Release Underlies Acid-Induced Mast Cell Activation in Functional Dyspepsia.
Sarnelli G; Pesce M; Seguella L; Lu J; Efficie E; Tack J; Elisa De Palma FD; D'Alessandro A; Esposito G
Cell Mol Gastroenterol Hepatol; 2021; 11(3):841-855. PubMed ID: 33065341
[TBL] [Abstract][Full Text] [Related]
9. The Protective Effects of Pre- and Post-Administration of Micronized Palmitoylethanolamide Formulation on Postoperative Pain in Rats.
Siracusa R; Fusco R; Cordaro M; Peritore AF; D'Amico R; Gugliandolo E; Crupi R; Genovese T; Evangelista M; Di Paola R; Cuzzocrea S; Impellizzeri D
Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33080989
[TBL] [Abstract][Full Text] [Related]
10. Glia and mast cells as targets for palmitoylethanolamide, an anti-inflammatory and neuroprotective lipid mediator.
Skaper SD; Facci L; Giusti P
Mol Neurobiol; 2013 Oct; 48(2):340-52. PubMed ID: 23813098
[TBL] [Abstract][Full Text] [Related]
11. Palmitoylethanolamide in CNS health and disease.
Mattace Raso G; Russo R; Calignano A; Meli R
Pharmacol Res; 2014 Aug; 86():32-41. PubMed ID: 24844438
[TBL] [Abstract][Full Text] [Related]
12. Systemic administration of oleoylethanolamide protects from neuroinflammation and anhedonia induced by LPS in rats.
Sayd A; Antón M; Alén F; Caso JR; Pavón J; Leza JC; Rodríguez de Fonseca F; García-Bueno B; Orio L
Int J Neuropsychopharmacol; 2014 Dec; 18(6):. PubMed ID: 25548106
[TBL] [Abstract][Full Text] [Related]
13. Palmitoylethanolamide, a Special Food for Medical Purposes, in the Treatment of Chronic Pain: A Pooled Data Meta-analysis.
Paladini A; Fusco M; Cenacchi T; Schievano C; Piroli A; Varrassi G
Pain Physician; 2016 Feb; 19(2):11-24. PubMed ID: 26815246
[TBL] [Abstract][Full Text] [Related]
14. Palmitoylethanolamide and Its Biobehavioral Correlates in Autism Spectrum Disorder: A Systematic Review of Human and Animal Evidence.
Colizzi M; Bortoletto R; Costa R; Zoccante L
Nutrients; 2021 Apr; 13(4):. PubMed ID: 33919499
[TBL] [Abstract][Full Text] [Related]
15. The pharmacology of palmitoylethanolamide and first data on the therapeutic efficacy of some of its new formulations.
Petrosino S; Di Marzo V
Br J Pharmacol; 2017 Jun; 174(11):1349-1365. PubMed ID: 27539936
[TBL] [Abstract][Full Text] [Related]
16. Levels of endocannabinoids and palmitoylethanolamide and their pharmacological manipulation in chronic granulomatous inflammation in rats.
; De Filippis D; D'Amico A; Cipriano M; Petrosino S; Orlando P; Di Marzo V; Iuvone T
Pharmacol Res; 2010 Apr; 61(4):321-8. PubMed ID: 19931394
[TBL] [Abstract][Full Text] [Related]
17. GPR119 and GPR55 as Receptors for Fatty Acid Ethanolamides, Oleoylethanolamide and Palmitoylethanolamide.
Im DS
Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33494185
[TBL] [Abstract][Full Text] [Related]
18. Neuroglial roots of neurodegenerative diseases: therapeutic potential of palmitoylethanolamide in models of Alzheimer's disease.
Scuderi C; Steardo L
CNS Neurol Disord Drug Targets; 2013 Feb; 12(1):62-9. PubMed ID: 23394526
[TBL] [Abstract][Full Text] [Related]
19. Synergic Therapeutic Potential of PEA-Um Treatment and NAAA Enzyme Silencing In the Management of Neuroinflammation.
Casili G; Lanza M; Campolo M; Siracusa R; Paterniti I; Ardizzone A; Scuderi SA; Cuzzocrea S; Esposito E
Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33050589
[TBL] [Abstract][Full Text] [Related]
20. Second-Generation Non-Covalent NAAA Inhibitors are Protective in a Model of Multiple Sclerosis.
Migliore M; Pontis S; Fuentes de Arriba AL; Realini N; Torrente E; Armirotti A; Romeo E; Di Martino S; Russo D; Pizzirani D; Summa M; Lanfranco M; Ottonello G; Busquet P; Jung KM; Garcia-Guzman M; Heim R; Scarpelli R; Piomelli D
Angew Chem Int Ed Engl; 2016 Sep; 55(37):11193-11197. PubMed ID: 27404798
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
